Genome Analyzer for the Institute of Diabetes, Obesity, and Metabolism

描述（由申请人提供）： 摘要资金要求Illumina基因组分析仪IIX和相关的集群站，以支持正在进行的NIH资助的PI发起的研究计划，在功能基因组学核心的糖尿病，肥胖和代谢研究所（IDOM），以及新的表观基因组学计划在宾夕法尼亚大学医学院。这些都是非常令人兴奋的计划，通过认识到环境因素，包括饮食和生活方式，通过基因表达的表观遗传调控影响糖尿病和肥胖表型的发展。功能基因组学核心已经建立了超高通量测序能力，得到了机构基金的支持。随着专注于表观基因组学和基因表达的九位主要研究人员的成功和生产力，包括PI和宾夕法尼亚大学的新高级招聘人员，对当前仪器的需求如此之大，以至于用户必须等待4-6周才能分析他们的样品，即使仪器不停地运行。目前和未来的全基因组转录因子结合、表观遗传图谱、microRNA发现和候选人类疾病区域的重新测序研究对于我们正在取得的快速进展至关重要，而拟议收购的第二台Illumina基因组分析仪IIX将使我们能够跟上不断增长的需求。宾夕法尼亚大学医学院已对这一努力作出了重大的财政承诺，包括本提案未涵盖的设备和服务合同费用的资金，以及功能基因组学核心的工作人员，这本身就是宾夕法尼亚大学NIDDK资助的糖尿病和内分泌研究中心的关键组成部分。此外，该机构还在新的Fisher转化研究大楼分配了专用空间来容纳仪器及其相关硬件，功能基因组学核心，IDOM和表观基因组学计划将位于同一地点。医学院还提供了一个大型服务器室和所需的超高速连接数据存储和访问。科学监督将由一个委员会完成，该委员会由提案的PI、IDOM主任和来自用户组的两名教师代表组成。因此，Illumina基因组分析仪将被专注于表观基因组和基因组研究的杰出、资金充足的研究人员高度利用，这些研究可能对糖尿病和肥胖等重大疾病产生关键影响。

DESCRIPTION (provided by applicant): Abstract Funds are requested for an Illumina Genome Analyzer IIX and associated Cluster Station to support the ongoing NIH-funded PI-initiated research programs in the Functional Genomics Core of the Institute for Diabetes, Obesity, and Metabolism (IDOM) as well as the new Epigenomics Program at the University of Pennsylvania School of Medicine. These are very exciting programs, linked by the recognition that environmental factors, including diet and lifestyle, influence the development of diabetes and obesity phenotypes via epigenetic regulation of gene expression. The Functional Genomics Core has already established an ultra- high throughput sequencing capability, supported by institutional funds. With the success and productivity of the nine major investigators focused on epigenomics and gene expression, including the PI and new senior recruits to the University of Pennsylvania, the demand on the current instrumentation is so great that users must wait 4-6 weeks for their samples to be analyzed, even with the instrument running non-stop. The current and future studies of genome-wide transcription factor binding, epigenetic mapping, microRNA discovery, and re- sequencing of candidate human disease regions are critical for the rapid progress we are making, and the proposed acquisition of a second Illumina Genome Analyzer IIX will allow us keep up with the increased demand. The University of Pennsylvania School of Medicine has made a major financial commitment towards this effort, including the funding of equipment and service contract costs not covered by this proposal as well as the staff of the Functional Genomics Core, which is itself a key component of Penn's NIDDK-funded Diabetes and Endocrinology Research Center. In addition, the institution has allocated dedicated space to house the instrument and its associated hardware in the new Fisher Translational Research Building, where the Functional Genomics Core, IDOM, and Epigenomics Program will be co- located. The School of Medicine has also provided a large server room and the required ultra- high speed connections for data storage and access. Scientific oversight will be accomplished by a committee comprised of the PI of the proposal, the IDOM director, and two faculty representatives from the user group. Thus, the Illumina Genome Analyzer will be highly utilized by outstanding, well-funded investigators focused on epigenomic and genomic research with the potential to have a critical impact on major diseases, including diabetes and obesity.